Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Michelson

Showing results (51-60 of 89) with videos related to

Pageof 9
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's diseaseTiffini Voss, Jerry Li, Jeffrey Cummings, et al.
Neurology|May 12, 2017
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson diseaseFabrizio Stocchi, Olivier Rascol, Robert A Hauser, et al.
European Child & Adolescent Psychiatry|March 9, 2006
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorderPhilip Hazell, Shuyu Zhang, Tomasz Wolańczyk, et al.
Human Psychopharmacology|March 28, 2013
Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophreniaMichael F Egan, Xin Zhao, Andrew Smith, et al.
Journal of Sleep Research|August 2, 2021
Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's diseaseVladimir Svetnik, Ting-Chuan Wang, Paulette Ceesay, et al.
The Journal of Clinical Psychiatry|May 4, 2007
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled studyDavid Michelson, Lenard A Adler, Jay D Amsterdam, et al.
The Pediatric Infectious Disease Journal|August 31, 2006
Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control studyPaula Ray, Jean Hayward, David Michelson, et al.
Surgical Endoscopy|December 30, 2025
International expert consensus on metric-based characterization of robot-assisted total laparoscopic hysterectomy (RATLH)Margarita Afonina, Arnold Advincula, Martin Martino, et al.
Pain|December 28, 2010
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic painDavid J Hewitt, Tony W Ho, Bradley Galer, et al.
Journal of Clinical Psychopharmacology|January 8, 2004
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessmentJoachim F Wernicke, Lenard Adler, Thomas Spencer, et al.
Pageof 9

Showing results (51-60 of 89) with videos related to

Sort By:
Pageof 9
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's diseaseTiffini Voss, Jerry Li, Jeffrey Cummings, et al.
Neurology|May 12, 2017
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson diseaseFabrizio Stocchi, Olivier Rascol, Robert A Hauser, et al.
European Child & Adolescent Psychiatry|March 9, 2006
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorderPhilip Hazell, Shuyu Zhang, Tomasz Wolańczyk, et al.
Human Psychopharmacology|March 28, 2013
Randomized controlled study of the T-type calcium channel antagonist MK-8998 for the treatment of acute psychosis in patients with schizophreniaMichael F Egan, Xin Zhao, Andrew Smith, et al.
Journal of Sleep Research|August 2, 2021
Pilot evaluation of a consumer wearable device to assess sleep in a clinical polysomnography trial of suvorexant for treating insomnia in patients with Alzheimer's diseaseVladimir Svetnik, Ting-Chuan Wang, Paulette Ceesay, et al.
The Journal of Clinical Psychiatry|May 4, 2007
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled studyDavid Michelson, Lenard A Adler, Jay D Amsterdam, et al.
The Pediatric Infectious Disease Journal|August 31, 2006
Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control studyPaula Ray, Jean Hayward, David Michelson, et al.
Surgical Endoscopy|December 30, 2025
International expert consensus on metric-based characterization of robot-assisted total laparoscopic hysterectomy (RATLH)Margarita Afonina, Arnold Advincula, Martin Martino, et al.
Pain|December 28, 2010
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic painDavid J Hewitt, Tony W Ho, Bradley Galer, et al.
Journal of Clinical Psychopharmacology|January 8, 2004
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessmentJoachim F Wernicke, Lenard Adler, Thomas Spencer, et al.
Pageof 9